The Drugs Controller General of India(DGCI), the head of the department of the Central Drugs Standard Control Organization gave its nod for emergency use of 2-DG drug developed by Defence Research and Development Organisation to treat Covid patients.
The 2-DG drug was approved for emergency use. Following this, as many as 10,000 doses of DRDO vaccines are likely to be launched by Saturday.
The (2-DG) drug was developed by the INMAS section of DRDO in collaboration with Dr. Reddy's Laboratories, based out of Hyderabad. DRDO claimed that the drug will help patients in recovering from the virus quickly.
(2-DG) drug, the DRDO's drug works in a way that the glucose powder identifies the cells that were damaged by Corona. After identifying the cells, the powder sees that the virus won't get the required energy. Without energy, the virus gets weak, so the virus can get developed.
After the DCGI approved the drug for emergency usage, the DRDO in a statement said that the clinical trials of the drug said that, the molecule helps hospitalized patients recover from the virus quickly.
With the help of the Centre for Cellular and Molecular Biology (CCMB), Hyderabad, the INMAS-DRDO scientists carried out experiments in labs and the molecule was found working against the Covid causing SARS-CoV-2 virus.